Sound corporate governance and high standards of ethical behavior are essential in sustaining our growth and success as a company, and in maintaining the trust and confidence of our stakeholders. Corporate governance at Actelion is designed to promote the long-term interests of our shareholders, maintain internal checks and balances, strengthen management accountability and foster responsible decision‑making.
Actelion continues to build on the strong foundation of current governance practices by updating or developing new Charters and Policies.
During 2014, we updated our Code of Business Conduct (“the Code”). The revised Code underpins our commitment to integrity and sets out fundamental rules for interacting with others as we drive our business forward. Supporting policies, standard operating procedures and guidelines provide more detail on how our high-level commitments should be applied in practice. Compliance with the Code is mandatory, and training is prescribed for all Actelion employees.
A new Code app was also rolled out to all computers and mobile devices. The app comprises the key principles and the full Code in eleven languages, as well as instant access to compliance professionals. In addition, it offers a practical Moral Compass, which helps colleagues consider important dimensions when taking decisions.
Clinical trials are essential to the development of innovative medicines. Actelion is committed to the highest quality and ethical standards in all our clinical research. Our trials are performed in accordance with internationally accepted guidelines, and protocols are evaluated by independent review boards and ethics committees prior to study initiation. We are also dedicated to enhancing public health through responsible clinical trial information transparency which respects our proprietary information, patients’ privacy, laws and regulations. In addition to our existing clinical trial disclosure activities, we are committed to implementing the Principles for Responsible Clinical Trial Data Sharing jointly issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).
We have a fundamental responsibility to market our medicines in a way that enhances patient care by helping healthcare professionals to make informed prescribing decisions. Ensuring high ethical standards in all our sales and marketing activities is a top priority, and all colleagues who interact with healthcare professionals receive specific training as part of our overall commitment to responsible business practices. Our policies regarding interaction with healthcare professionals are based on industry best practices, including the provisions of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice, the updated PhRMA Code on Interactions with Healthcare Professionals and other applicable industry codes.